{
    "nctId": "NCT00841399",
    "briefTitle": "Safety and Efficacy Study of HER2/Neu (E75) Vaccine in Node-Positive Breast Cancer Patients",
    "officialTitle": "Phase Ib Trial of HER2/Neu Peptide (E75) Vaccine in Breast Cancer Patients at Risk for Recurrence After Surgical and Medical Therapies",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "PREVENTION",
    "enrollmentCount": 100,
    "primaryOutcomeMeasure": "The primary endpoints are the safety and optimal dosing of the vaccine to induce an in vivo peptide-specific immune response.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. HER2/neu expressing tumor\n2. HLA-A2+ and/or HLA-A3+ to receive the vaccine. HLA-A2- and/or HLA-A3- patients will be eligible to be included in the control group.\n3. Immunologically intact with a good performance status\n4. Identified as being high or intermediate risk for recurrence\n5. Without evidence of disease\n6. Completion of all standard first-line therapies (but may still be on hormonal therapy)\n\nExclusion Criteria:\n\n1. Tumor does not express HER2/neu\n2. Not HLA-A2+ and/or HLA-A3+\n3. Anergic\n4. Receiving immunosuppressive therapy\n5. In poor health (Karnofsky \\<60%, ECOG \\>2 and Tbili \\>1.5 and creatinine\\>2)\n6. Pregnant (beta HCG+)\n7. Metastatic disease or have refused standard therapies\n8. Patients enrolled in other experimental protocols may enroll to this study only with the permission of the other study PI.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}